James Wang

发表

Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.

Shuxia Zhao, Leigh Zawel, Stephen Fawell, 2013, Cancer discovery.

MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo

Sylvain Lefebvre, Daniel Delorme, A. Kalita, 2008, Molecular Cancer Therapeutics.

Identification of a Novel Series of Potent TrkA Receptor Tyrosine Kinase Inhibitors

C. Maroun, S. Raeppel, F. Gaudette, 2012, International journal of medicinal chemistry.

N-(2-Amino-phenyl)-4-(heteroarylmethyl)-benzamides as new histone deacetylase inhibitors.

M. Robert, A. Macleod, O. Moradei, 2007, Bioorganic & medicinal chemistry letters.

Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity.

O. Moradei, S. Leit, S. Fréchette, 2007, Journal of medicinal chemistry.

Discovery of bicyclic pyrazoles as class III histone deacetylase SIRT1 and SIRT2 inhibitors.

Eric Therrien, M. Fournel, Zuomei Li, 2015, Bioorganic & medicinal chemistry letters.

Discovery of hydroxyaniline amides as selective Extracellular Regulated Kinase (Erk) inhibitors.

W. Windsor, A. Samatar, D. Carr, 2015, Bioorganic & medicinal chemistry letters.

Discovery of 3-morpholino-imidazole[1,5-a]pyrazine BTK inhibitors for rheumatoid arthritis.

T. Fischmann, K. Maloney, C. Garlisi, 2017, Bioorganic & medicinal chemistry letters.

SAR and biological evaluation of analogues of a small molecule histone deacetylase inhibitor N-(2-aminophenyl)-4-((4-(pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzamide (MGCD0103).

A. Kalita, O. Moradei, S. Leit, 2009, Bioorganic & medicinal chemistry letters.

Discovery of novel BTK inhibitors with carboxylic acids.

T. Fischmann, K. Maloney, C. Garlisi, 2017, Bioorganic & medicinal chemistry letters.

Discovery of 8-Amino-imidazo[1,5-a]pyrazines as Reversible BTK Inhibitors for the Treatment of Rheumatoid Arthritis.

V. Hornak, T. Fischmann, K. Maloney, 2016, ACS medicinal chemistry letters.

Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases.

M. Robert, A. Macleod, A. Vaisburg, 2008, Bioorganic & Medicinal Chemistry Letters.

N3-arylmalonamides: a new series of thieno[3,2-b]pyridine based inhibitors of c-Met and VEGFR2 tyrosine kinases.

A. Macleod, Nancy Z. Zhou, S. Raeppel, 2009, Bioorganic & medicinal chemistry letters.

(2-Amino-phenyl)-amides of ω-substituted alkanoic acids as new histone deacetylase inhibitors

A. Kalita, A. Macleod, O. Moradei, 2004 .

Potent, non-covalent reversible BTK inhibitors with 8-amino-imidazo[1,5-a]pyrazine core featuring 3-position bicyclic ring substitutes.

T. Fischmann, K. Maloney, C. Garlisi, 2020, Bioorganic & medicinal chemistry letters.

Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor.

Isabelle Paquin, Daniel Delorme, A. Kalita, 2008, Journal of medicinal chemistry.

(2-amino-phenyl)-amides of omega-substituted alkanoic acids as new histone deacetylase inhibitors.

A. Kalita, A. Macleod, O. Moradei, 2004, Bioorganic & medicinal chemistry letters.

MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology.

K. Cox, P. Kirschmeier, R. Doll, 2018, ACS medicinal chemistry letters.

Discovery of 3(S)-thiomethyl pyrrolidine ERK inhibitors for oncology.

P. Kirschmeier, R. Doll, W. Windsor, 2018, Bioorganic & medicinal chemistry letters.

Identification of a novel series of potent RON receptor tyrosine kinase inhibitors.

C. Maroun, A. Macleod, S. Raeppel, 2010, Bioorganic & medicinal chemistry letters.

Synthesis and evaluation of lysine derived sulfamides as histone deacetylase inhibitors.

Alain Ajamian, Sylvain Lefebvre, Alina Nicolescu, 2009, Bioorganic & medicinal chemistry letters.

N-(3-fluoro-4-(2-arylthieno[3,2-b]pyridin-7-yloxy)phenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors.

M. Robert, Nancy Z. Zhou, S. Raeppel, 2009, Bioorganic & medicinal chemistry letters.

N-(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors.

Sylvain Lefebvre, M. Robert, Nancy Z. Zhou, 2009, Bioorganic & medicinal chemistry letters.

Abstract 930: Preclinical characterization of MG516, a novel inhibitor of receptor tyrosine kinases involved in resistance to targeted therapies.

C. Maroun, S. Raeppel, A. Vaisburg, 2013 .

312 A Novel Assay for the Met Inhibitory Activity of MGCD265 in Plasma From Solid Tumor Patients in a Dose Escalating Phase I Study

G. Shapiro, H. Hurwitz, C. Maroun, 2012 .

MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo

A. Kalita, M. Robert, A. Macleod, 2008, Molecular Cancer Therapeutics.